Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume
January 25 2022 - 7:30AM
AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or
“we”) (ANPC), a biotechnology company with operations in the United
States and China focused on early cancer screening and detection,
announced today that Frost & Sullivan Company (“Sullivan”), a
leading and well-known US market analysis and research firm has
ranked AnPac Bio globally as number one in worldwide multiple
cancer screening and detection volume in a recent research report
(based on data accumulated through the end of 2020), which included
next generation cancer screening and detection technologies,
including circulating tumor cells (CTCs), circulating-DNA (CT-DNA),
exosome, cancer differentiation analysis (CDA), mRNA, and other
emerging technologies. Specifically, for next generation
cancer screening and detection, the Sullivan research report ranked
AnPac Bio globally as number one in total volume of multi-cancer
screening and detection, with 216,600 detection tests, while GRAIL
Company was ranked globally number two with 135,100 detection
tests. In the category of volume of commercial
multi-cancer tests (for next generation cancer screening and
detection), AnPac Bio was ranked global number one as well with
172,900 detection tests.
Since 2010, AnPac Bio has been a thought leader, major
innovator, and champion of multi-cancer testing. The Company
has made significant contributions to the ideas, technology
development and practice in this field, as recorded and evidenced
by its multiple patent filings going back over ten years,
announcement in 2014 with the successful development and launch of
a novel technology capable of detecting 16 types of cancer
diseases, and publications of four technical papers at 2015 ASCO
meeting.
Dr. Chris Yu, CEO and Chairman of AnPac Bio commented:
“We are very pleased with this significant global number one
ranking, which signifies AnPac Bio as a global leader and the most
accepted player in the field of multi-cancer screening and
detection. The increasing volume in multi-cancer screening and
detection indicates that our multi-cancer vision is clearly
winning. We are even more excited by the progress in our
multi-cancer screening platform and that more and more experts and
customers are embracing this novel and great idea. We
will work very hard to ensure that our multi-cancer screening and
detection technology will continue to be adopted by the population
and will save millions of lives.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer
screening and detection, with 150 issued patents as of September
30, 2021. With two certified clinical laboratories in China and one
CLIA and CAP accredited clinical laboratory in the United States,
AnPac Bio performs a suite of cancer screening and detection tests,
including CDA (Cancer Differentiation Analysis), bio-chemical,
immunological, and genomics tests. According to Frost &
Sullivan, AnPac Bio is number one in total volume of multi-cancer
screening and detection, with 216,600 detection tests. AnPac Bio’s
CDA technology platform has been shown in retrospective validation
studies to be able to detect the risk of over 20 different cancer
types with high sensitivity and specificity.
For more information, please visit:
https://www.Anpacbio.com.
For investor and media inquiries, please
contact:
Company:Phil Case, Marketing and Investor RelationsPhone:
+1-267-810-6776 (US)Email: phil_case@AnPacbio.com
Investor Relations:Ascent Investor Relations LLCTina Xiao,
PresidentPhone: +1-917-609-0333
(US)Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company's future financial and operating
performance. The Company has attempted to identify forward-looking
statements by terminologies including "believes," "estimates,"
"anticipates," "expects," "plans," "projects," "intends,"
"potential," “target,” “aim,” “predict,” “outlook,” “seek,” “goal”
“objective,” “assume,” “contemplate,” “continue,” “positioned,”
“forecast,” “likely,” "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
the implementation of our business model and growth strategies;
trends and competition in the cancer screening and detection
market; our expectations regarding demand for and market acceptance
of our cancer screening and detection tests and our ability to
expand our customer base; our ability to obtain and maintain
intellectual property protections for our CDA technology and our
continued research and development to keep pace with technology
developments; our ability to obtain and maintain regulatory
approvals from the NMPA, the FDA and the relevant U.S. states and
have our laboratories certified or accredited by authorities
including the CLIA; our future business development, financial
condition and results of operations and our ability to obtain
financing cost-effectively; potential changes of government
regulations; general economic and business conditions in China and
elsewhere; our ability to hire and maintain key personnel; our
relationship with our major business partners and customers; and
the duration of the coronavirus outbreaks and their potential
adverse impact on the economic conditions and financial markets and
our business and financial performance, such as resulting from
reduced commercial activities due to quarantines and travel
restrictions instituted by China, the U.S. and many other countries
around the world to contain the spread of the virus. Additionally,
all forward-looking statements are subject to the “Risk Factors”
detailed from time to time in the Company's most recent Annual
Report on Form 20-F and other filings with the U.S. Securities and
Exchange Commission. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Sep 2023 to Sep 2024